Skip to content
Study details
Enrolling now

Prazosin for Alcohol Use Disorder With Withdrawal Symptoms

Yale University
NCT IDNCT04793685ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

150

Study length

about 6 years

Ages

18–70

Locations

1 site in CT

What this study is about

Researchers are testing whether Prazosin (16mg/day) helps people with alcohol use disorder and withdrawal symptoms. Participants will receive weekly counseling to support their recovery, along with either Prazosin or a placebo medication over 12 weeks. The trial will also assess drinking patterns like heavy drinking days and no heavy drinking days.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Participate in 12-Step Facilitation with Relapse Prevention and Contingency Management
  • 2.Take Prazosin

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Oral

How treatment is administered

Treatment Assignment
Randomized & Blinded

You may get a placebo/standard care, and you won't know which.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

prazosin (Alpha-1 blocker; relaxes blood vessels and prostate)

Drug routes

oral (Oral Capsule)

Body systems

Psychiatry / Mental Health